| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/26/2006 | US7112667 Sequences of an Ih ion channel and use thereof |
| 09/26/2006 | US7112612 N-alkylated GABA compounds, processes for their preparation and their use as medicaments |
| 09/26/2006 | US7112608 Hydroxyphenylundecane, a process for their production and their use |
| 09/26/2006 | US7112607 Antihypoxic agents, antiischamic agents, antiarrhythmia agents |
| 09/26/2006 | US7112603 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 09/26/2006 | US7112598 κ opioid receptor agonist comprising 2-phenylbenzothiazoline derivative |
| 09/26/2006 | US7112583 Containing a benzodiazepine ring, e.g., (2(R)-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; treating Alzheimer's disease and Down's Syndrome |
| 09/26/2006 | US7112574 found to be potent adenosine receptor agonists, in particular for the A2A receptor. |
| 09/26/2006 | US7112568 an anti-allergic agent, comprising a molecule having at least a first segment competent for importation of the molecule into mast cells, and a second segment for having an anti-allergic effect within the mast cells |
| 09/26/2006 | US7112427 Protein comprising mitogenic kinase activity for identifying modulators of inflammation, apoptosis and cell proliferation; antiproliferative agents |
| 09/26/2006 | US7112421 Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related thereto |
| 09/26/2006 | US7112321 Amyothropic lateral sclerosis; gene therapy |
| 09/26/2006 | CA2254561C Method of producing dry thioctic acid |
| 09/21/2006 | WO2006099480A2 Stress proteins and peptides and methods of use thereof |
| 09/21/2006 | WO2006099459A1 Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine |
| 09/21/2006 | WO2006099457A1 (s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof |
| 09/21/2006 | WO2006099452A1 Anhydrous ziprasidone mesylate and a process for its preparation |
| 09/21/2006 | WO2006099433A1 Pure duloxetine hydrochloride |
| 09/21/2006 | WO2006099379A2 Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors |
| 09/21/2006 | WO2006099352A1 Novel isophthalates as beta-secretase inhibitors |
| 09/21/2006 | WO2006099351A2 Hydrocodone polymorphs |
| 09/21/2006 | WO2006098834A2 Crystalline forms of ziprasidone mesylate |
| 09/21/2006 | WO2006098520A1 Screening method |
| 09/21/2006 | WO2006098519A1 Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof |
| 09/21/2006 | WO2006098488A1 Method of ameliorating symptom caused by mood disturbance |
| 09/21/2006 | WO2006097970A1 Use of inhibitors of steroid (testosterone) activity (i. a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse |
| 09/21/2006 | WO2006097766A1 Arylsulfonyl benzyl ethers as 5-ht2a antagonists |
| 09/21/2006 | WO2006097759A1 Perfume compositions |
| 09/21/2006 | WO2006097691A1 Fused thiazole derivatives having affinity for the histamine h3 receptor |
| 09/21/2006 | WO2006097459A1 Method for preventing cardiovascular diseases |
| 09/21/2006 | WO2006097416A1 Compounds for use in the prevention and treatment of alzheimer's disease |
| 09/21/2006 | WO2006097270A1 Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as maob inhibitors |
| 09/21/2006 | WO2006097043A1 Bacopa monnieri extract and process for preparation and use thereof |
| 09/21/2006 | WO2006079547A3 Spm 927 for add-on therapy of schizophrenia |
| 09/21/2006 | WO2006079077A3 Use of diltiazem or analogs thereof as modulators of ghrelin receptor |
| 09/21/2006 | WO2006061373A3 Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites |
| 09/21/2006 | WO2006047330A3 Methylphenidate analogs and methods of use thereof |
| 09/21/2006 | WO2006031267A3 Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| 09/21/2006 | WO2006002422A9 Compounds for immunopotentiation |
| 09/21/2006 | WO2006002421A3 Modulators of atp-binding cassette transporters |
| 09/21/2006 | WO2005120456A3 Formulation of eletriptan |
| 09/21/2006 | WO2005112897A3 Immediate release pharmaceutical tablets with height greater than width |
| 09/21/2006 | US20060211865 Use of pyridine N-oxide analogs at doses which do not induce emesis |
| 09/21/2006 | US20060211860 Compounds for the treatment of Alzheimer's disease |
| 09/21/2006 | US20060211764 Cell activator, process for producing cell activator and apparatus therefor |
| 09/21/2006 | US20060211735 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor |
| 09/21/2006 | US20060211734 (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists |
| 09/21/2006 | US20060211703 Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions |
| 09/21/2006 | US20060211696 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND |
| 09/21/2006 | US20060211694 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease |
| 09/21/2006 | US20060211691 Use of 2h-[1,3]-oxazino[3,2-a] indole derivatives for the treatment of neuropathic pain |
| 09/21/2006 | US20060211688 Vehicle for topical delivery of anti-inflammatory compounds |
| 09/21/2006 | US20060211679 Substituted lactams as inhibitors of Abeta protein production |
| 09/21/2006 | US20060211664 Method for treating erectile dysfunction and increasing libido in men |
| 09/21/2006 | US20060211618 Polynucleotides and polypeptides of the erythropoietin gene |
| 09/21/2006 | US20060211609 Novel agent for improving neurotransmission failure |
| 09/21/2006 | US20060211607 Somatostatin-dopamine chimeric analogs |
| 09/21/2006 | US20060211602 Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 09/21/2006 | US20060211148 Protein biopolymer markers indicative of age matched control |
| 09/21/2006 | US20060211147 Protein biopolymer markers indicative of age matched control |
| 09/21/2006 | US20060211144 Protein biopolymer markers indicative of age matched control |
| 09/21/2006 | US20060210964 Prevention and treatment of amyloid-associated disorders |
| 09/21/2006 | US20060210647 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| 09/21/2006 | US20060210624 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs |
| 09/21/2006 | US20060210589 With botulinum toxin |
| 09/21/2006 | US20060210535 Means for regulating the expression of human isoforms of ant |
| 09/21/2006 | DE102005012681A1 New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer |
| 09/21/2006 | DE102005011517A1 Transdermales therapeutisches System zur Verabreichung von Analgetika Transdermal therapeutic system for administration of analgesics |
| 09/21/2006 | CA2621943A1 Hydrocodone polymorphs |
| 09/21/2006 | CA2601831A1 Combination of sodium channel blockers and their derivatives with opioid antagonists |
| 09/21/2006 | CA2601717A1 Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof |
| 09/21/2006 | CA2601644A1 Fused thiazole derivatives having affinity for the histamine h3 receptor |
| 09/21/2006 | CA2601503A1 Phenol derivatives and their use to modulate pkb activity |
| 09/21/2006 | CA2601227A1 Mecano growth factor peptides and their use |
| 09/21/2006 | CA2601051A1 Use of inhibitors of steroid (testosterone) activity (i. a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse |
| 09/21/2006 | CA2600822A1 Method for preventing cardiovascular diseases |
| 09/21/2006 | CA2600761A1 Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as maob inhibitors |
| 09/21/2006 | CA2600508A1 Arylsulfonyl benzyl ethers as 5-ht2a antagonists |
| 09/21/2006 | CA2599478A1 Process for the purification of duloxetine hydrochloride |
| 09/21/2006 | CA2599475A1 Pure duloxetine hydrochloride |
| 09/21/2006 | CA2599391A1 Crystalline forms of ziprasidone mesylate |
| 09/20/2006 | EP1702985A2 Preferred segments of neural thread protein and methods of using the same |
| 09/20/2006 | EP1702920A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/20/2006 | EP1702919A1 Novel 2-heteroaryl-substituted benzimidazole derivative |
| 09/20/2006 | EP1702627A1 Analgesic combination of sodium channel blockers with opioid antagonists |
| 09/20/2006 | EP1702626A1 Inhibitor for the formation of gammad-secretase complex |
| 09/20/2006 | EP1702617A1 Cannabimimetic indole derivatives |
| 09/20/2006 | EP1701959A1 Triazole derivatives as vasopressin antagonists |
| 09/20/2006 | EP1701954A1 N-substituted piperidine and piperazine derivatives |
| 09/20/2006 | EP1701933A1 Novel compounds |
| 09/20/2006 | EP1701730A2 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| 09/20/2006 | EP1701725A1 Methods and compositions |
| 09/20/2006 | EP1701688A2 Methods and compositions for directing migration of neural progenitor cells |
| 09/20/2006 | EP1554253A4 Imidazolium cxcr3 inhibitors |
| 09/20/2006 | EP1549624A4 Inhibitors of fatty acid amide hydrolase |
| 09/20/2006 | EP1487835B1 Amides of acetic and propionic acids |
| 09/20/2006 | EP1392363B1 Use of mGLuR5 antagonists in the manufacture of a medicament in the treatment of Fragile X syndrome, Autism and Mental Retardation |
| 09/20/2006 | EP1368364B1 C2, 8-disubstituted adenosine derivatives and their different uses |
| 09/20/2006 | EP1353916B1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/20/2006 | EP1292621B1 Compositions for treating autoimmune disease |